Human embryonic stem cells (and therapeutic stem cells in general) culture in densely packed colonies, or aggregates, and by far the best method for passaging these cultures is with dissociated single cells. However, the current methods of enzymatic and chemical dissociation induce extreme variation in gene expression and cell viability1,2 — ultimately leading to failed or unreproducible trials — and lack easy scalability. Manual dissection greatly improves survivability but cripples efficiency. These problems have heretofore prevented stem cell therapies from becoming clinically relevant.
Premature differentiation and cell death can be mitigated by mechanical dissociation.3 Our proprietary technology automatically and continuously generates a single-cell suspension by applying laminar shear stress to cell aggregates — dissociating aggregates without altering the differentiation trajectory or karyotype of the cell culture, returning equal or greater viability.
Preliminary tests of the Dissociator™ have demonstrated high viability with flow rates up to 37 mL/min per device, and many Dissociators can be operated in parallel by a single technician to accommodate larger bioreactors — achieving speeds up to 36 times faster than today's standard. The Dissociator can be appended to a standard luer taper syringe, or it can be run in feedback with a bioreactor via a peristaltic pump.
We are seeking funding for our remaining research and development. We would also like to entertain partnership proposals from research labs and other entities with which we have mutual interest. To learn more or get involved, email us at email@example.com.